Phathom Pharmaceuticals, Inc. — Form 8-K Summary
Business Context and Reporting Period
Phathom Pharmaceuticals, Inc. filed a Current Report on Form 8-K dated March 7, 2024, under Item 2.02 to announce financial results for the quarter and year ended December 31, 2023. The filing relates to the company’s common stock, traded on Nasdaq under the symbol PHAT.
Financial Results and Key Metrics
The supplied filing text does not provide the underlying revenue, profit or loss, cash flow, margin, debt, liquidity, or other financial figures. It states that these results were included in the press release filed as Exhibit 99.1.
Material Changes Versus the Prior Comparable Period
The filing text does not provide comparative financial data or describe material changes versus the prior quarter or year.
Guidance, Outlook, Risks, and Unusual Items
The supplied text does not include management guidance, outlook commentary, risk updates, contingencies, or unusual items. The filing notes that the Form 8-K and Exhibit 99.1 are furnished pursuant to General Instruction B.2 and are not deemed filed for purposes of Section 18 of the Exchange Act, except as expressly provided by reference.
Investor Verification Items
- Review Exhibit 99.1 for the complete quarterly and annual financial results.
- Verify revenue, net loss, operating expenses, cash and cash equivalents, cash runway, debt, and cash-flow figures in the press release or related filings.
- Review any guidance, product-development updates, regulatory matters, and going-concern or liquidity disclosures included in Exhibit 99.1.
- Confirm the filing’s furnished-not-filed status and the scope of any incorporation by reference in subsequent filings.